Indaptus Therapeutics (NASDAQ:INDP) Posts Earnings Results, Beats Estimates By $0.03 EPS

Indaptus Therapeutics (NASDAQ:INDP) announced its quarterly earnings results on Thursday. The company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.41) by $0.03, Zacks reports.

Indaptus Therapeutics Price Performance

Shares of NASDAQ:INDP traded up $0.00 during trading hours on Friday, hitting $0.81. The company’s stock had a trading volume of 2,761 shares, compared to its average volume of 45,358. The firm’s fifty day moving average price is $0.86 and its 200 day moving average price is $1.09. Indaptus Therapeutics has a 52 week low of $0.70 and a 52 week high of $3.10. The company has a market capitalization of $11.44 million, a price-to-earnings ratio of -0.47 and a beta of 1.60.

Indaptus Therapeutics Company Profile

Indaptus Therapeutics, Inc, a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial.